European Journal of Pharmaceutics and Biopharmaceutics, 2010, Vol.74(2), pp.157-163
Poly(lactide-co-glycolide) (PLGA) nanoparticles coated with poloxamer 188 (Pluronic F-68) or polysorbate 80 (Tween 80) enable an efficient brain delivery of the drugs after intravenous injection. This ability was evidenced by two different pharmacological test systems employing as model drugs the anti-tumour antibiotic doxorubicin and the agonist of opioid receptors loperamide, which being P-gp substrates can cross the blood–brain barrier (BBB) only in pharmacologically insignificant amounts: binding of doxorubicin to the surfactant-coated PLGA nanoparticles, however, enabled a high anti-tumour effect against an intracranial 101/8 glioblastoma in rats, and the penetration of nanoparticle-bound loperamide into the brain was demonstrated by the induction of central analgesic effects in mice. Both pharmacological tests could demonstrate that therapeutic amounts of the drugs were delivered to the sites of action in the brain and showed the high efficiency of the surfactant-coated PLGA nanoparticles for brain delivery. The results of the study also demonstrated that the efficacy of brain delivery by nanoparticles not only is influenced by the coating surfactants but also by other formulation parameters such as core polymer, drug, and stabilizer.
Blood–Brain Barrier ; Doxorubicin ; Glioblastoma ; Loperamide ; Mice ; Nanoparticles ; Poly(Lactide-Co-Glycolide) ; Poloxamer 188 ; Polysorbate 80 ; Rats ; Tail-Flick Test ; Pharmacy, Therapeutics, & Pharmacology
View record in ScienceDirect (Access to full text may be restricted)